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The diagnosis of metastatic prostate carcinoma frequently
requires the use of immunohistochemical adjuncts. Immunohisto-
chemistry for prostate-specific antigen (PSA) is commonly used
for this purpose but can be of limited utility. Recently, prostate-
specific membrane antigen (PSMA) has been shown to be a
promising marker for the identification of metastatic prostate
carcinoma in surgical specimens. The utility of this marker has
yet to be reported for cytology specimens. We sought to com-
pare the sensitivities of PSMA and PSA immunohistochemistry
and investigate the specificity of PSMA by utilizing cell block
preparations from cytologic cases of metastatic prostate carci-
noma (n5 19) and carcinomas of nonprostatic origin (n5 33).
The sensitivity of PSMA immunohistochemistry was higher (16/
19; 84%) in detecting metastatic prostate carcinomas than that
of PSA immunohistochemistry (11/19; 58%). Strong, diffuse
staining for PSMA was seen in 13 (81%) of 16 PSMA-positive
cases whereas strong, diffuse staining for PSA was observed in
six (55%) of 11 PSA-positive cases. Positivity for either PSMA
or PSA was seen in 17 of 19 cases of metastatic prostate carci-
noma for a combined sensitivity of 89%. PSMA immunohisto-
chemistry was completely negative in 32 of 33 cytology cases of
nonprostatic carcinomas. Therefore, the specificity of this
marker was 97% in this study. In conclusion, our results indi-
cate that PSMA is a highly sensitive and specific immunomarker
for the detection of metastatic prostate carcinoma in cytology
specimens. Diagn. Cytopathol. 2014;42:570–575. VC 2013 Wiley
Periodicals, Inc.
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INTRODUCTION
Prostate cancer is the most common noncutaneous malig-
nancy in adult men. In 2013, it is estimated that there
will be 238,590 new cases of prostate cancer and 29,720
prostate cancer-related deaths.1 Although most men are
diagnosed with localized disease, a significant subset of
patients is diagnosed with locoregional disease spread
and/or distant metastases or will develop metastasis later
in the course of their disease.2 Although surgery for local-
ized prostate cancer can be curative, the treatment for
metastatic disease involves antiandrogen therapy, chemo-
therapy, immunotherapy, and/or radiation.3–7 Accurate
diagnosis of metastatic prostate carcinoma is essential for
the timely management of patients with metastatic
disease.
Cytologic samples, including fine-needle aspiration (FNA)
and effusion specimens, represent a rapid, minimally inva-
sive, relatively inexpensive means to identify and diagnose
metastatic prostate cancer. Although the diagnosis of well-
differentiated metastatic prostate cancers can be straightfor-
ward, the diagnosis of higher-grade, poorly differentiated
tumors can be challenging.8 Compounding this problem,
studies have shown that metastatic prostate carcinoma can
present in a different morphologic pattern compared to that
of the primary tumor.9–12 Thus, immunohistochemistry can
serve as a useful adjunct in this regard. Traditionally, anti-
bodies directed against prostate-specific antigen (PSA) and
prostate acid phosphatase (PAP) are used for this purpose.
Nonetheless, negative immunoreactivity for both of these
markers in a significant subset of metastatic prostate carcino-
mas, especially higher-grade tumors, can contribute to diag-
nostic difficulties.13,14
Prostate-specific membrane antigen (PSMA) expres-
sion is present in both benign and neoplastic prostatic
tissue,15–24 and its expression is stronger in the lat-
ter.17,21,22 Expression has also been shown to be
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greatest, with respect to immunostaining intensity and
extent, in high-grade prostate carcinomas compared to
low-grade carcinomas.20,22 We are not aware of any
reports in the literature, to date, that examine the utility
of PSMA immunohistochemistry in the diagnosis of met-
astatic prostate cancer in cytology specimens. Therefore,
the aims of this study were 2-fold. First, we sought to
compare the performance of PSMA and PSA immuno-
histochemistry for the detection of metastatic prostate
carcinomas. Next, we performed PSMA immunohisto-
chemistry for cytologic specimens of nonprostate carci-
nomas to better understand the diagnostic specificity of
this marker.
MATERIALS AND METHODS
The study was approved by the institutional review board
at University of Michigan. The electronic pathology data-
base was searched, using the search terms “prostate” or
“prostatic,” to identify reports of potential cytologic cases
of prostatic carcinoma. A total of 21 cases, in which
tumor cells were present in the cell block, were identified.
Clinicopathologic evaluation utilizing the electronic medi-
cal record (clinical notes, radiology reports, and pathol-
ogy reports) was performed and confirmed metastatic
prostatic carcinoma in 19 of these cases (Table I). In two
cases, nonprostatic origin was confirmed and these two
cases were included in the nonprostatic carcinoma control
cohort (cases 1 and 2, Table II). The control cohort also
consisted of 4, 5, 12, and 10 consecutive cases of urothe-
lial, gastrointestinal, lung, and renal carcinomas diag-
nosed in men, respectively, for which the cell blocks
contained adequate material for immunohistochemical
evaluation (cases 3–33, Table II). For these cases, the
electronic medical records (clinical notes, radiology
reports, and pathology reports) were reviewed in conjunc-
tion with the original diagnostic slides to confirm the pri-
mary site of malignancy. Unstained sections of 4-mm
thickness were prepared from each of the formalin-fixed,
paraffin-embedded cell blocks.
Immunohistochemistry for PSMA was performed
using the Ventana Benchmark Ultra (Ventana, Tucson,
AZ) using 3,30-diaminobenzidine as the chromogen. Fol-
lowing deparaffinization, antigen retrieval was












1 Soft tissue, left T4-T5
paraspinal/epidural
mass
Unknown Unknown Positive (5) Positive (6)
2 Bone, right scapula
lesion
7 Unknown Positive (6) Negative (0)
3 Lymph node, left
cervical
Unknown Unknown Positive (6) Positive (3)
4 Lymph node, left
inguinal
9 T3b N0 Mx Positive (6) Positive (5)
5 Lymph node, left
supraclavicular
9 T1c Nx Mx Positive (4) Negative (2)
6 Soft tissue, mediastinal
mass
7 T3a N0 Mx Positive (6) Positive (6)
7 Bone, left posterior rib
lesion
8 T3b N0 Mx Positive (6) Positive (6)
8 Lymph node, subcarinal 7 T1c Nx Mx Positive (6) Positive (6)
9 Lymph node, subcarinal 10 T2a N0 M0 Positive (5) Positive (5)
10 Voided urine 7 T2a N0 M0 Positive (6) Positive (6)
11 Lymph node, mediastinal
4R
7 Unknown Positive (6) Negative (0)
12 Lymph node, left
cervical
9 T3a N1 Mx Positive (6) Positive (4)
13 Soft tissue, penis lesion 7 T1c Nx Mx Positive (6) Negative (0)
14 Bone, right inferior
pubic ramus lesion
8 T1c Nx M1b Negative (2) Positive (3)
15 Right pleural fluid 9 T1c N1 M1b Positive (6) Positive (6)
16 Right pleural fluid Unknown Unknown Positive (6) Negative (0)
17 Lymph node, right
inguinal
5 Unknown Positive (6) Negative (0)
18 Left pleural fluid 7 T1c Nx M0 Negative (0) Negative (0)
19 Left pleural fluid 7 T2a N0 M0 Negative (0) Negative (0)
Sensitivity 84% (16/19) 58% (11/19)
aStage was determined according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th ed.
bRefers to combined immunoreactivity score (see Materials and Methods section).
PSMA, prostate-specific membrane antigen; PSA, prostate-specific antigen.
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performed on unstained cell block sections using CC1
buffer, pH 8.5 (Ventana, Tucson, AZ). Subsequently,
immunohistochemistry was performed using the mouse
monoclonal anti-PSMA antibody (3E6; 1:25 dilution;
DAKO, Carpinteria, CA) along with appropriate con-
trols. The UltraView Universal DAB Detection Kit
(Ventana, Tucson, AZ) was used for detection of mouse
primary antibodies.
Immunohistochemistry for PSA was performed using the
DAKO Autostainer (DAKO, Carpinteria, CA) using 3,30-dia-
minobenzidine as the chromogen. Immunohistochemistry
was performed using the rabbit polyclonal anti-PSA antibody
(1:3000 dilution; DAKO, Carpinteria, CA) following antigen
retrieval in 0.01M citrate buffer, pH 6.0 (DAKO, Carpinteria,
CA) along with appropriate controls. The EnVision1 System
for use with rabbit primary antibodies (DAKO, Carpinteria,
CA) was used as the secondary antibody.
Immunostained slides were reviewed (K.D.B. and
M.H.R.) and scored for both intensity of staining (0, nega-
tive; 1, weak intensity; 2, moderate intensity; 3, strong
intensity) and extent of staining (0, 0% of cells; 1, <10%
of cells; 2, 10–50% of cells; 3, >50% of cells). The com-
bined immunoreactivity score was recorded by taking the
sum of the scores for intensity and extent of staining. A
combined immunoreactivity score of 3 or greater was con-
sidered as a positive result. Completely negative staining
or weak, very focal staining (combined immunoreactivity
score of 2) were both considered as negative results.
RESULTS
Cytology cases of metastatic prostatic carcinoma, obtained
from 19 patients, were examined in this study. The ana-
tomic sites from which the cytologic samples were obtained
are listed in Table I. Sixteen (84%) of the 19 metastatic
prostatic carcinoma cases were scored as positive for
PSMA (Table I). Staining intensity in all 16 PSMA-
positive cases ranged from moderate to strong. Notably,
strong, diffuse staining in the tumor cells (combined immu-
noreactivity score of 6) was observed in 13 of 16 PSMA-
positive cases. Of the three cases that were scored as
PSMA-negative, two had complete absence of staining and
Table II. PSMA Expression in Metastatic Carcinomas of Extraprostatic Origin
Case Primary malignancy Source of cytologic specimen
PSMA staining
result (scorea)
1 Invasive extramammary Paget’s disease Lymph node, left inguinal Negative (0)
2 Esophageal squamous cell carcinoma Lymph node, right supraclavicular Negative (0)
3 Urothelial carcinoma Lymph node, left inguinal Negative (0)
4 Urothelial carcinoma Lymph node, left inguinal Negative (0)
5 Urothelial carcinoma Lymph node, mediastinal station 7 Negative (0)
6 Urothelial carcinoma Right pleural fluid Negative (0)
7 Rectal adenocarcinoma Colon, rectal mass Negative (0)
8 Gastric cardia adenocarcinoma Ascites fluid Negative (0)
9 Gastroesophageal junction
adenosquamous carcinoma
Soft tissue, periportal mass Negative (0)
10 Colonic adenocarcinoma Soft tissue, retroperitoneal nodule Negative (0)
11 Esophageal adenocarcinoma Pericardial fluid Negative (0)
12 Pulmonary adenocarcinoma Lymph node, mediastinal station 7 Negative (0)
13 Pulmonary adenocarcinoma Lymph node, mediastinal station 4R Negative (0)
14 Pulmonary adenocarcinoma Soft tissue, peribronchial mass Negative (0)
15 Pulmonary adenocarcinoma Lymph node, mediastinal station 10L Negative (0)
16 Pulmonary adenocarcinoma Lymph node, mediastinal station 4R Positive (3)
17 Pulmonary adenocarcinoma Lymph node, mediastinal station 4R Negative (0)
18 Pulmonary adenocarcinoma Lymph node, mediastinal station 7 Negative (0)
19 Pulmonary adenocarcinoma Lymph node, mediastinal station 4R Negative (0)
20 Pulmonary adenocarcinoma Lymph node, mediastinal station 11R Negative (0)
21 Pulmonary adenocarcinoma Lymph node, mediastinal station 4R Negative (0)
22 Pulmonary adenocarcinoma Lymph node, mediastinal station 2R Negative (0)
23 Pulmonary adenocarcinoma Lung, left upper lobe mass Negative (0)
24 Renal cell carcinoma Pericardial fluid Negative (0)
25 Renal cell carcinoma Lymph node, pararenal Negative (0)
26 Renal cell carcinoma Lymph node, paratracheal Negative (0)
27 Renal cell carcinoma Lymph node, paratracheal Negative (0)
28 Renal cell carcinoma Pancreas, pancreatic head mass Negative (0)
29 Renal cell carcinoma Lymph node, mediastinal station 4R Negative (0)
30 Renal cell carcinoma Kidney, left renal mass Negative (0)
31 Renal cell carcinoma Kidney, right renal mass Negative (0)
32 Renal cell carcinoma Left pleural fluid Negative (0)
33 Renal cell carcinoma Bone, T6 vertebral lesion Negative (0)
aRefers to combined immunoreactivity score (see Materials and Methods section).
PSMA, prostate-specific membrane antigen.
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one exhibited faint staining in less than 10% of the tumor
cells (combined immunoreactivity score of 2).
Eleven (58%) of the 19 metastatic prostatic carcinoma
cases scored positive for PSA (Table I). Six of the 11
PSA-positive cases exhibited strong, diffuse staining
(combined immunoreactivity score of 6). The remaining
five PSA-positive cases varied in staining intensity and
extent with combined immunoreactivity scores of 3–5. Of
the eight cases that were scored as PSA-negative, seven
exhibited a complete absence of staining, and one demon-
strated faint staining in less than 10% of the tumor cells
(combined immunoreactivity score of 2).
Overall, the sensitivity of PSMA immunohistochemis-
try was higher than that of PSA immunohistochemistry
(84 vs. 58%, respectively). For 10 cases, both immuno-
stains were scored as positive (Figs. 1A–C). Seventeen of
Fig. 1. Immunohistochemistry for PSMA and PSA for cases of metastatic prostate carcinoma. (A, D, G, J) Representative photomicrographs obtained
from hematoxylin and eosin (H&E) stained cell block sections derived from cases of metastatic prostate carcinoma (cases 6, 11, 14, and 19, respec-
tively). (B, E, H, K) Corresponding immunohistochemical stains for PSMA expression. In panels B and E, strong diffuse staining for PSMA is demon-
strated (combined immunoreactivity score of 6). PSMA immunostains in panels H and K were interpreted as negative. (C, F, I, L) Corresponding
immunohistochemical stains for PSA expression. In panel C, strong diffuse staining for PSA is demonstrated (combined immunoreactivity score of 6).
The PSA immunostains in panels F and L were interpreted as negative. The PSA immunostain for case 14 (panel I) was interpreted as positive; weak
staining intensity was noted in greater than 10% but less than 50% of the tumor cells (combined immunoreactivity score of 3). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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19 cases were positive for either PSMA or PSA for a
combined sensitivity of 89%. Six of the eight PSA-
negative cases were PSMA-positive (Figs. 1D–F). One
case was scored as PSMA-negative and PSA-positive
(Figs. 1G–I). Two cases of metastatic prostate carcinoma
were negative for both PSA and PSMA (Figs. 1J–L).
Finally, we sought to investigate the specificity of
PSMA as a diagnostic immunomarker by examining, in
parallel, cytology specimens obtained from 33 male
patients with carcinomas of extraprostatic origin. The pri-
mary malignancy and anatomic sites from which the cyto-
logic samples were obtained are indicated in Table II. In
this cohort, PSMA positivity was only seen in one case
of a metastatic pulmonary adenocarcinoma (Table II, case
16). In this case, PSMA immunoreactivity of moderate
intensity was observed in less than 10% of the tumor
cells (not shown). The remaining 32 cases of nonprostatic
carcinoma were completely negative for PSMA. There-
fore, in our study, the specificity of PSMA positivity for
identifying metastatic prostate carcinoma was 97%.
DISCUSSION
To our knowledge, there are no reports, to date, that exam-
ine the utility of immunohistochemistry for PSMA in the
evaluation of metastatic prostate carcinomas in cytology
specimens. PSA and PAP immunohistochemistry have
been traditionally utilized for this purpose; nonetheless, the
efficacy of these markers is limited as a significant propor-
tion of metastatic prostate carcinoma cases are negative for
both markers. Our immunoperoxidase laboratory has vali-
dated the anti-PSMA antibody for clinical use. This marker
is used routinely by our surgical pathology colleagues;
they have observed a higher sensitivity of PSMA immuno-
histochemistry, compared to PSA, for confirming meta-
static prostate carcinoma. In our study, the observed
sensitivity of PSMA immunohistochemistry in highlighting
metastatic prostate carcinoma tumor cells in cell block
sections was 84%. This is consistent with previous studies
that observed PSMA immunoreactivity ranging from 66 to
100% in surgical pathology samples.15–22,25–28 Importantly,
we compared the performance of PSMA immunohisto-
chemistry to that of PSA immunohistochemistry and
observed that the former is more reliable. Specifically,
strong diffuse staining of tumor cells was seen at higher
frequency on PSMA immunohistochemistry than on PSA
immunohistochemistry. The overall sensitivity of PSMA
immunohistochemistry (84%) was higher than that of PSA
immunohistochemistry (58%).
The relatively high sensitivity of PSMA immunohisto-
chemistry in metastatic prostate carcinoma samples is not
surprising. Previous reports indicate that, on immunohis-
tochemistry, PSMA expression is robust and observed for
both low and high-grade prostate cancers.20,22 In contrast,
well-differentiated prostate carcinomas are more likely
than higher-grade cancers to express PSA on immunohis-
tochemistry.13,14 High-grade carcinomas exhibit higher
metastatic potential than their well-differentiated counter-
parts. Sensitivities ranging from 81 to 100% have been
reported for the immunohistochemical detection of PSMA
in metastatic prostate cancers.16,17,19,20,23 Furthermore,
PSMA expression was shown to be higher in cases of
prostate cancers that metastasize to lymph nodes17 and
bone.20 The biological mechanism underlying the
increased expression of PSMA relative to PSA in higher
grade, more aggressive prostate cancers is not exactly
known. Although some have speculated that PSMA over-
expression drives prostate cancer tumorigenesis, this has
not been rigorously proven.21 Thus, our results corrobo-
rate these previous reports and indicate that PSMA is a
more efficacious immunomarker in the cytodiagnostic
workup of metastatic carcinomas that originate from the
prostate gland.
Highly sensitive immunomarkers raise concern with
regards to the specificity of the marker being evaluated.
We sought to investigate the specificity of this marker in
our study by performing PSMA immunohistochemistry on
cell block sections of nonprostatic carcinomas. We tested
tumors of various primary sites such as lung, kidney, and
gastrointestinal tract. These tumors especially metastasize
to similar anatomic sites as prostate cancers, as evidenced
by Tables I and II, and can represent cytomorphologic
mimics of metastatic prostate carcinoma. Of these tumors,
PSMA-negative results were obtained for all cases except
for one case of lung carcinoma. Therefore, although the
specificity of PSMA immunohistochemistry is not perfect,
it remains very high (97%). Mhawech-Fauceglia et al.
observed weak immunoreactivity for PSMA in a small pro-
portion of various nonprostatic carcinomas such as gastric,
colonic, gall bladder, pancreas, and lung.18 Nonetheless,
the specificity of strong, diffuse PSMA staining for meta-
static prostate carcinomas was very high. Of note, Lane
et al. observed that approximately 11% of bladder adeno-
carcinomas stained positively for PSMA in a diffuse fash-
ion.29 Therefore, despite the relative rarity of these tumors
compared to prostate carcinomas, care should be exercised
when adenocarcinomas of the bladder are considered
within the differential diagnostic workup. In light of these
reports, it is important to emphasize that in our cohort,
strong diffuse PSMA staining was observed in the majority
of our metastatic prostate carcinoma cases.
In conclusion, immunohistochemistry for PSMA is
more sensitive than that for PSA in the cytodiagnostic
workup of metastatic prostate cancers. Of note, the com-
bination of PSMA and PSA immunohistochemistry was
slightly more sensitive than the sensitivity of utilizing
PSMA immunohistochemistry alone. As we now and
others previously have demonstrated the high sensitivity
and specificity for PSMA immunohistochemistry, we
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believe that PSMA represents a valuable component to
the immunohistochemical armamentarium for confirming
prostatic origin for metastatic prostate carcinomas in diag-
nostic cytology.
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